Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,659
archived clinical trials in
Metabolic

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 (ENGAGE)
Status: Enrolling
Updated:  10/16/2015
University hospital "Alexandrovska" Sofia
mi
from
Sofia,
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 (ENGAGE)
Status: Enrolling
Updated: 10/16/2015
University hospital "Alexandrovska" Sofia
mi
from
Sofia,
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients
A Phase 2, Open-Label, Multi-Center Study Evaluating the Efficacy, Safety and Pharmacokinetics of Genz-112638 in Gaucher Type 1 Patients
Status: Enrolling
Updated:  10/16/2015
New York University
mi
from
New York, NY
A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients
A Phase 2, Open-Label, Multi-Center Study Evaluating the Efficacy, Safety and Pharmacokinetics of Genz-112638 in Gaucher Type 1 Patients
Status: Enrolling
Updated: 10/16/2015
New York University
mi
from
New York, NY
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients
A Phase 2, Open-Label, Multi-Center Study Evaluating the Efficacy, Safety and Pharmacokinetics of Genz-112638 in Gaucher Type 1 Patients
Status: Enrolling
Updated:  10/16/2015
Clinical Research Facility
mi
from
New York, NY
A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients
A Phase 2, Open-Label, Multi-Center Study Evaluating the Efficacy, Safety and Pharmacokinetics of Genz-112638 in Gaucher Type 1 Patients
Status: Enrolling
Updated: 10/16/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients
A Phase 2, Open-Label, Multi-Center Study Evaluating the Efficacy, Safety and Pharmacokinetics of Genz-112638 in Gaucher Type 1 Patients
Status: Enrolling
Updated:  10/16/2015
Aprillus Asistencia e Investigación
mi
from
Buenos Aires,
A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients
A Phase 2, Open-Label, Multi-Center Study Evaluating the Efficacy, Safety and Pharmacokinetics of Genz-112638 in Gaucher Type 1 Patients
Status: Enrolling
Updated: 10/16/2015
Aprillus Asistencia e Investigación
mi
from
Buenos Aires,
Click here to add this to my saved trials
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms
Status: Enrolling
Updated:  10/16/2015
Clinical Research Facility
mi
from
Decatur, GA
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms
Status: Enrolling
Updated: 10/16/2015
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms
Status: Enrolling
Updated:  10/16/2015
Clinical Research Facility
mi
from
Cincinnati, OH
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms
Status: Enrolling
Updated: 10/16/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms
Status: Enrolling
Updated:  10/16/2015
Clinical Research Facility
mi
from
Seattle, WA
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms
Status: Enrolling
Updated: 10/16/2015
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms
Status: Enrolling
Updated:  10/16/2015
mi
from
Buenos Aires,
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms
Status: Enrolling
Updated: 10/16/2015
mi
from
Buenos Aires,
Click here to add this to my saved trials
Vitamin E Treatment for Long-Chain 3-Hydroxyacyl Coenzyme A (CoA) Dehydrogenase (LCHAD) Associated Neuropathy
Vitamin E Treatment for LCHAD Associated Neuropathy
Status: Enrolling
Updated:  10/20/2015
Oregon Health and Sciences University
mi
from
Portland, OR
Vitamin E Treatment for Long-Chain 3-Hydroxyacyl Coenzyme A (CoA) Dehydrogenase (LCHAD) Associated Neuropathy
Vitamin E Treatment for LCHAD Associated Neuropathy
Status: Enrolling
Updated: 10/20/2015
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
Fish Oil Study for High Triglyceride Levels in Children
Fish Oil Treatment for Dyslipidemia Associated With Children and Adolescents
Status: Enrolling
Updated:  11/4/2015
A. I. duPont Hospital for Children
mi
from
Wilmington, DE
Fish Oil Study for High Triglyceride Levels in Children
Fish Oil Treatment for Dyslipidemia Associated With Children and Adolescents
Status: Enrolling
Updated: 11/4/2015
A. I. duPont Hospital for Children
mi
from
Wilmington, DE
Click here to add this to my saved trials
Fish Oil Study for High Triglyceride Levels in Children
Fish Oil Treatment for Dyslipidemia Associated With Children and Adolescents
Status: Enrolling
Updated:  11/4/2015
Johns Hopkins Hospital
mi
from
Baltimore, MD
Fish Oil Study for High Triglyceride Levels in Children
Fish Oil Treatment for Dyslipidemia Associated With Children and Adolescents
Status: Enrolling
Updated: 11/4/2015
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Fish Oil Study for High Triglyceride Levels in Children
Fish Oil Treatment for Dyslipidemia Associated With Children and Adolescents
Status: Enrolling
Updated:  11/4/2015
Thomas Jefferon University
mi
from
Philadelphia, PA
Fish Oil Study for High Triglyceride Levels in Children
Fish Oil Treatment for Dyslipidemia Associated With Children and Adolescents
Status: Enrolling
Updated: 11/4/2015
Thomas Jefferon University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Natural History Studies of Mucopolysaccharidosis III
Natural History Studies of Mucopolysaccharidosis III
Status: Enrolling
Updated:  11/12/2015
Nationwide Children's Hospital
mi
from
Columbus, OH
Natural History Studies of Mucopolysaccharidosis III
Natural History Studies of Mucopolysaccharidosis III
Status: Enrolling
Updated: 11/12/2015
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Vitamin A, Stool Microbiota and Vaccine Response in Bangladeshi Infants
Newborn Vitamin A Supplementation, Gut Microbiota and Vaccine Response During the Second Year of Life in Bangladeshi Infants
Status: Enrolling
Updated:  11/17/2015
University of California Davis
mi
from
Davis, CA
Vitamin A, Stool Microbiota and Vaccine Response in Bangladeshi Infants
Newborn Vitamin A Supplementation, Gut Microbiota and Vaccine Response During the Second Year of Life in Bangladeshi Infants
Status: Enrolling
Updated: 11/17/2015
University of California Davis
mi
from
Davis, CA
Click here to add this to my saved trials
Vitamin A, Stool Microbiota and Vaccine Response in Bangladeshi Infants
Newborn Vitamin A Supplementation, Gut Microbiota and Vaccine Response During the Second Year of Life in Bangladeshi Infants
Status: Enrolling
Updated:  11/17/2015
USDA-Western Human Nutrition Research Center
mi
from
Davis, CA
Vitamin A, Stool Microbiota and Vaccine Response in Bangladeshi Infants
Newborn Vitamin A Supplementation, Gut Microbiota and Vaccine Response During the Second Year of Life in Bangladeshi Infants
Status: Enrolling
Updated: 11/17/2015
USDA-Western Human Nutrition Research Center
mi
from
Davis, CA
Click here to add this to my saved trials
Vitamin A, Stool Microbiota and Vaccine Response in Bangladeshi Infants
Newborn Vitamin A Supplementation, Gut Microbiota and Vaccine Response During the Second Year of Life in Bangladeshi Infants
Status: Enrolling
Updated:  11/17/2015
International Centre for Diarrhoeal Disease Research, Bangladesh
mi
from
Dhaka,
Vitamin A, Stool Microbiota and Vaccine Response in Bangladeshi Infants
Newborn Vitamin A Supplementation, Gut Microbiota and Vaccine Response During the Second Year of Life in Bangladeshi Infants
Status: Enrolling
Updated: 11/17/2015
International Centre for Diarrhoeal Disease Research, Bangladesh
mi
from
Dhaka,
Click here to add this to my saved trials
Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
A Phase 2 Safety Study in Which Ischemic Stroke Patients Will be Randomized Within 24 Hours of Symptom Onset to Placebo or Oral Lovastatin 640 mg Per Day for 3 Days.
Status: Enrolling
Updated:  12/7/2015
University of California, Los Angeles Stroke Network
mi
from
Los Angeles, CA
Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
A Phase 2 Safety Study in Which Ischemic Stroke Patients Will be Randomized Within 24 Hours of Symptom Onset to Placebo or Oral Lovastatin 640 mg Per Day for 3 Days.
Status: Enrolling
Updated: 12/7/2015
University of California, Los Angeles Stroke Network
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
A Phase 2 Safety Study in Which Ischemic Stroke Patients Will be Randomized Within 24 Hours of Symptom Onset to Placebo or Oral Lovastatin 640 mg Per Day for 3 Days.
Status: Enrolling
Updated:  12/7/2015
Jackson Memorial Hospital
mi
from
Miami, FL
Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
A Phase 2 Safety Study in Which Ischemic Stroke Patients Will be Randomized Within 24 Hours of Symptom Onset to Placebo or Oral Lovastatin 640 mg Per Day for 3 Days.
Status: Enrolling
Updated: 12/7/2015
Jackson Memorial Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
A Phase 2 Safety Study in Which Ischemic Stroke Patients Will be Randomized Within 24 Hours of Symptom Onset to Placebo or Oral Lovastatin 640 mg Per Day for 3 Days.
Status: Enrolling
Updated:  12/7/2015
University of Miami Miller School of Medicine
mi
from
Miami, FL
Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
A Phase 2 Safety Study in Which Ischemic Stroke Patients Will be Randomized Within 24 Hours of Symptom Onset to Placebo or Oral Lovastatin 640 mg Per Day for 3 Days.
Status: Enrolling
Updated: 12/7/2015
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
A Phase 2 Safety Study in Which Ischemic Stroke Patients Will be Randomized Within 24 Hours of Symptom Onset to Placebo or Oral Lovastatin 640 mg Per Day for 3 Days.
Status: Enrolling
Updated:  12/7/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
A Phase 2 Safety Study in Which Ischemic Stroke Patients Will be Randomized Within 24 Hours of Symptom Onset to Placebo or Oral Lovastatin 640 mg Per Day for 3 Days.
Status: Enrolling
Updated: 12/7/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
A Phase 2 Safety Study in Which Ischemic Stroke Patients Will be Randomized Within 24 Hours of Symptom Onset to Placebo or Oral Lovastatin 640 mg Per Day for 3 Days.
Status: Enrolling
Updated:  12/7/2015
Emory University
mi
from
Atlanta, GA
Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
A Phase 2 Safety Study in Which Ischemic Stroke Patients Will be Randomized Within 24 Hours of Symptom Onset to Placebo or Oral Lovastatin 640 mg Per Day for 3 Days.
Status: Enrolling
Updated: 12/7/2015
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
A Phase 2 Safety Study in Which Ischemic Stroke Patients Will be Randomized Within 24 Hours of Symptom Onset to Placebo or Oral Lovastatin 640 mg Per Day for 3 Days.
Status: Enrolling
Updated:  12/7/2015
Mount Sinai School of Medicine
mi
from
New York, NY
Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
A Phase 2 Safety Study in Which Ischemic Stroke Patients Will be Randomized Within 24 Hours of Symptom Onset to Placebo or Oral Lovastatin 640 mg Per Day for 3 Days.
Status: Enrolling
Updated: 12/7/2015
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
A Phase 2 Safety Study in Which Ischemic Stroke Patients Will be Randomized Within 24 Hours of Symptom Onset to Placebo or Oral Lovastatin 640 mg Per Day for 3 Days.
Status: Enrolling
Updated:  12/7/2015
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
A Phase 2 Safety Study in Which Ischemic Stroke Patients Will be Randomized Within 24 Hours of Symptom Onset to Placebo or Oral Lovastatin 640 mg Per Day for 3 Days.
Status: Enrolling
Updated: 12/7/2015
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation
A Phase 2, Open-label, Multinational Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Who Have Limited Ambulation
Status: Enrolling
Updated:  12/8/2015
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation
A Phase 2, Open-label, Multinational Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Who Have Limited Ambulation
Status: Enrolling
Updated: 12/8/2015
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation
A Phase 2, Open-label, Multinational Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Who Have Limited Ambulation
Status: Enrolling
Updated:  12/8/2015
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation
A Phase 2, Open-label, Multinational Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Who Have Limited Ambulation
Status: Enrolling
Updated: 12/8/2015
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation
A Phase 2, Open-label, Multinational Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Who Have Limited Ambulation
Status: Enrolling
Updated:  12/8/2015
Universitätsklinikum Hamburg
mi
from
Hamburg,
Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation
A Phase 2, Open-label, Multinational Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Who Have Limited Ambulation
Status: Enrolling
Updated: 12/8/2015
Universitätsklinikum Hamburg
mi
from
Hamburg,
Click here to add this to my saved trials
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated:  12/9/2015
Yale University School of Medicine
mi
from
New Haven, CT
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated: 12/9/2015
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated:  12/9/2015
Mount Sinai Hospital
mi
from
New York, NY
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated: 12/9/2015
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated:  12/9/2015
University of Utah
mi
from
Salt Lake City, UT
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated: 12/9/2015
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated:  12/9/2015
University of California San Diego Medical Center
mi
from
San Diego, CA
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated: 12/9/2015
University of California San Diego Medical Center
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated:  12/9/2015
Emory University Medical Center
mi
from
Decatur, GA
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated: 12/9/2015
Emory University Medical Center
mi
from
Decatur, GA
Click here to add this to my saved trials
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated:  12/9/2015
Children's Memorial Hospital
mi
from
Chicago, IL
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated: 12/9/2015
Children's Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated:  12/9/2015
New York University School of Medicine
mi
from
New York, NY
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated: 12/9/2015
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated:  12/9/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated: 12/9/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated:  12/9/2015
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated: 12/9/2015
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated:  12/9/2015
O & O Alpan
mi
from
Springfield, VA
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated: 12/9/2015
O & O Alpan
mi
from
Springfield, VA
Click here to add this to my saved trials
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated:  12/9/2015
Royal Prince Alfred Hospital
mi
from
Camperdown,
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Status: Enrolling
Updated: 12/9/2015
Royal Prince Alfred Hospital
mi
from
Camperdown,
Click here to add this to my saved trials
Natural History of Apparent Mineralocorticoid Excess Syndrome
Apparent Mineralocorticoid Excess Syndrome Natural History Clinical Protocol
Status: Enrolling
Updated:  12/10/2015
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Natural History of Apparent Mineralocorticoid Excess Syndrome
Apparent Mineralocorticoid Excess Syndrome Natural History Clinical Protocol
Status: Enrolling
Updated: 12/10/2015
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Natural History of Apparent Mineralocorticoid Excess Syndrome
Apparent Mineralocorticoid Excess Syndrome Natural History Clinical Protocol
Status: Enrolling
Updated:  12/10/2015
Mount Sinai School of Medicine
mi
from
New York, NY
Natural History of Apparent Mineralocorticoid Excess Syndrome
Apparent Mineralocorticoid Excess Syndrome Natural History Clinical Protocol
Status: Enrolling
Updated: 12/10/2015
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Natural History of Apparent Mineralocorticoid Excess Syndrome
Apparent Mineralocorticoid Excess Syndrome Natural History Clinical Protocol
Status: Enrolling
Updated:  12/10/2015
University of Sao Paulo
mi
from
Sao Paulo,
Natural History of Apparent Mineralocorticoid Excess Syndrome
Apparent Mineralocorticoid Excess Syndrome Natural History Clinical Protocol
Status: Enrolling
Updated: 12/10/2015
University of Sao Paulo
mi
from
Sao Paulo,
Click here to add this to my saved trials
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
St. Petersburg, FL
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Addison, IL
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Addison, IL
Click here to add this to my saved trials
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Louisville, KY
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Columbus, OH
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Kettering, OH
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Kettering, OH
Click here to add this to my saved trials
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Lyndhurst, OH
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Lyndhurst, OH
Click here to add this to my saved trials
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials